Bolsters Company's Corporate
Mission
Financing Led by Board Member and Priced at
Premium to Market Price
WEXFORD,
Pa., June 20, 2024 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, autoimmune, and infectious diseases,
is pleased to announce that it has closed on $4.3 million in a financing led by CJC Investment
Trust, an entity controlled by board member Christopher Calise.
Under the terms of the financing, the Series A Preferred is
convertible into shares of the Company's common stock at a price of
$0.40 per share, subject to
limitations. The investors also received in the aggregate a 6.45%
equity interest in two of the Company's newly formed subsidiaries,
SNAP Biosciences Inc. and GEAR Therapeutics Inc.
Dave Mehalick, President and CEO
of Coeptis Therapeutics said, "We are grateful for the continued
support from our investors, particularly in these transformative
times for Coeptis Therapeutics. These individuals share our passion
and long-term vision for Coeptis, and their support goes beyond
investment, reflecting a focus on the Company's future."
"This financing comes at an opportune moment as we are
anticipating several significant near-term milestones. The
commitment from our investors not only strengthens our balance
sheet but also bolsters our innovative cell therapy platforms and
long-term growth prospects."
Proceeds from this financing will be allocated towards repayment
of outstanding obligations, working capital, and general corporate
purposes.
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its subsidiaries
including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical company
developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio and rights are highlighted by
assets licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms, which Coeptis is developing with
VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is
designed around maximizing the value of its current product
portfolio and rights through in-license agreements, out-license
agreements and co-development relationships, as well as entering
into strategic partnerships to expand its product rights and
offerings, specifically those targeting cancer and infectious
diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our
management made in connection therewith contain or may contain
"forward-looking statements" (as defined in Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended). Forward-looking
statements include statements concerning our plans, objectives,
goals, strategies, future events or performance, and underlying
assumptions, and other statements that are other than statements of
historical facts. When we use words such as "may," "will,"
"intend," "should," "believe," "expect," "anticipate," "project,"
"estimate" or similar expressions that do not relate solely to
historical matters, we are making forward-looking statements.
Forward-looking statements are not a guarantee of future
performance and involve significant risks and uncertainties that
may cause the actual results to differ materially and perhaps
substantially from our expectations discussed in the
forward-looking statements. Factors that may cause such differences
include but are not limited to: (1) the inability to maintain the
listing of the Company's securities on the Nasdaq Capital Market;
(2) the inability to recognize the anticipated benefits of the
Deverra licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (3) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (4) costs related to ongoing asset
development including the Deverra licensed assets and pursuing the
contemplated asset development paths; (5) changes in applicable
laws or regulations; (6) the possibility that the Company may be
adversely affected by other economic, business, and/or competitive
factors; and (7) the impact of the global COVID-19 pandemic on any
of the foregoing risks and other risks and uncertainties identified
in the Company's filings with the Securities and Exchange
Commission (the "SEC"). The foregoing list of factors is not
exclusive. All forward-looking statements are subject to
significant uncertainties and risks including, but not limited, to
those risks contained or to be contained in reports and other
filings filed by the Company with the SEC. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings made or to be made
with the SEC, which are available for review at www.sec.gov. We
undertake no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the
date hereof unless required by applicable laws, regulations, or
rules.
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-closes-on-4-3-million-of-series-a-preferred-offering-302177491.html
SOURCE Coeptis Therapeutics